| Target
Information |
| Name | Muscarinic acetylcholine receptor M2 |
| Type of target | Successful target |
| Synonyms | M2 receptor |
| Disease | Alzheimer's disease [1] |
| Analgesics [2] |
| Autoimmune cardiomyopathy [3] |
| Bronchoconstriction (cold air-induced) [4] |
| Chronic obstructive pulmonary disease, unspecified [4] |
| Hypothermia [5] |
| Neurogenic bladder [6] |
| Pain, unspecified [2] |
| Tremor, unspecified [5] |
| Drug(s) | Gallamine Triethiodide |  | Approved | Stabilize muscle contractions | [7] |
| Methylscopolamine |  | Approved | Peptic ulcer disease | [8] |
| Scopolamine |  | Approved | Nausea and Addiction | [9][10] |
| BioChemical Class | G-protein coupled receptor (rhodopsin family) |
| Pathway | Calcium signaling pathway |
| Neuroactive ligand-receptor interaction |
| Regulation of actin cytoskeleton |
| UniProt ID | P08172 |
| PDB Structure | 1LUB. |
| Function | The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. |
| Sequence | MNNSTNSSNNSLALTSPYKTFEVVFIVLVAGSLSLVTIIGNILVMVSIKVNRHLQTVNNY
FLFSLACADLIIGVFSMNLYTLYTVIGYWPLGPVVCDLWLALDYVVSNASVMNLLIISFD
RYFCVTKPLTYPVKRTTKMAGMMIAAAWVLSFILWAPAILFWQFIVGVRTVEDGECYIQF
FSNAAVTFGTAIAAFYLPVIIMTVLYWHISRASKSRIKKDKKEPVANQDPVSPSLVQGRI
VKPNNNNMPSSDDGLEHNKIQNGKAPRDPVTENCVQGEEKESSNDSTSVSAVASNMRDDE
ITQDENTVSTSLGHSKDENSKQTCIRIGTKTPKSDSCTPTNTTVEVVGSSGQNGDEKQNI
VARKIVKMTKQPAKKKPPPSREKKVTRTILAILLAFIITWAPYNVMVLINTFCAPCIPNT
VWTIGYWLCYINSTINPACYALCNATFKKTFKHLLMCHYKNIGATR
|
| Related US Patent | 6,288,068 |
| 6,294,554 |
| 6,498,168 |
| 6,500,822 |
| 6,627,644 |
| 6,635,658 |
| 6,645,958 |
| 6,667,301 |
| Target Validation | Click to Find Target Validation Information. |
| Inhibitor | 1'-Benzyl-3-phenyl-[3,4']bipiperidinyl-2,6-dione |  | [11] |
| 1,1-diphenyl-2- (3-tropanyl)ethanol |  | [12] |
| 1-Methyl-1- (4-pyrrolidin-1-yl-but-2-ynyl)-urea |  | [13] |
| 2,8-Dimethyl-1-oxa-8-aza-spiro[4.5]decan-3-one |  | [14] |
| 2- (4-Diethylamino-but-2-ynyl)-isoindole-1,3-dione |  | [15] |
| 2-Methyl-6-pyrrolidin-1-yl-hex-4-ynal oxime |  | [16] |
| 3- (3-benzylamino)-piperidin-2-one |  | [17] |
| 3-Methyl-7-pyrrolidin-1-yl-hept-5-yn-2-one |  | [16] |
| 3-Tetrazol-2-yl-1-aza-bicyclo[2.2.2]octane |  | [18] |
| 4- (4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one |  | [19] |
| 6-Dimethylamino-2-methyl-hex-4-ynal oxime |  | [16] |
| 7-Dimethylamino-3-methyl-hept-5-yn-2-one |  | [16] |
| 7-Dimethylamino-hept-5-yn-2-one |  | [16] |
| 7-Dimethylamino-hept-5-yn-2-one oxime |  | [16] |
| 7-Pyrrolidin-1-yl-hept-5-yn-2-one |  | [16] |
| 7-Pyrrolidin-1-yl-hept-5-yn-2-one oxime |  | [16] |
| A-987306 |  | [20] |
| ACECLIDINE |  | [21] |
| Acetic acid 8-aza-bicyclo[3.2.1]oct-6-yl ester |  | [22] |
| BRL-55473 |  | [23] |
| Benzoic acid 8-aza-bicyclo[3.2.1]oct-6-yl ester |  | [24] |
| CARAMIPEN |  | [25] |
| FLUMEZAPINE |  | [26] |
| FM1-10 |  | [27] |
| FM1-43 |  | [27] |
| GNF-PF-5618 |  | [28] |
| HIMBACINE |  | [29] |
| ISOCLOZAPINE |  | [30] |
| ISOLOXAPINE |  | [31] |
| METHACHOLINE |  | [22] |
| METHOCTRAMINE |  | [20] |
| METHOCTRAMINE HYDROCHLORIDE |  | [32] |
| N- (4-Dimethylamino-but-2-ynyl)-N-methyl-acetamide |  | [16] |
| N-DESMETHYLCLOZAPINE |  | [19] |
| N-methoxyquinuclidine-3-carboximidoyl chloride |  | [23] |
| N-methoxyquinuclidine-3-carboximidoyl fluoride |  | [23] |
| Propionic acid 8-aza-bicyclo[3.2.1]oct-6-yl ester |  | [24] |
| SCH-211803 |  | [33] |
| SULFOARECOLINE |  | [34] |
| Tiotropium Bromide |  | [35] |
| XANOMELINE |  | [36] |
| Agonist | CMI-1145 |  | [2] |
| CMI-936 |  | [2] |
| Oxotremorine |  | [2] |
| PTAC |  | [4] |
| Antagonist | (R)-4-[2-[3- |  | [37][3] |
| AF-DX116 |  | [6] |
| Gallamine Triethiodide |  | [7] |
| Methylscopolamine |  | [8] |
| Otenzepad |  | [3] |
| Scopolamine |  | [9][10] |
| Cross References |
3D Structure
Related Literature
On-Line
Medical Dictionary |
| Ref 1 | Psychosis of Alzheimer's disease is associated with elevated muscarinic M2 binding in the cortex. Neurology. 2001 Sep 11;57(5):805-11. To Reference |
| Ref 2 | Evaluation of muscarinic agonist-induced analgesia in muscarinic acetylcholine receptor knockout mice. Mol Pharmacol. 2002 Nov;62(5):1084-93. To Reference |
| Ref 3 | Beneficial effect of muscarinic-2 antagonist on dilated cardiomyopathy induced by autoimmune mechanism against muscarinic-2 receptor. J Cardiovasc Pharmacol. 2001 Oct;38 Suppl 1:S43-9. To Reference |
| Ref 4 | Function of pulmonary neuronal M(2) muscarinic receptors in stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001 May;163(6):1320-5. To Reference |
| Ref 5 | Generation and pharmacological analysis of M2 and M4 muscarinic receptor knockout mice. Life Sci. 2001 Apr 27;68(22-23):2457-66. To Reference |
| Ref 6 | The effects of the antagonists of muscarinic acetylcholine receptor subtypes in rat brain on urinary bladder contraction. Nippon Hinyokika Gakkai Zasshi. 2002 Mar;93(3):427-34. To Reference |
| Ref 7 | Cholinergic regulation of the corpora allata in adult male loreyi leafworm Mythimna loreyi. Arch Insect Biochem Physiol. 2002 Apr;49(4):215-24. To Reference |
| Ref 8 | Methylacridinium and its Cholinergic Properties. Neurotox Res. 2009 Jun 30. [Epub ahead of print] To Reference |
| Ref 9 | The amygdala modulates morphine-induced state-dependent memory retrieval via muscarinic acetylcholine receptors. Neuroscience. 2009 May 5;160(2):255-63. Epub 2009 Mar 9. To Reference |
| Ref 10 | Midbrain acetylcholine and glutamate receptors modulate accumbal dopamine release. Neuroreport. 2008 Jun 11;19(9):991-5. To Reference |
| Ref 11 | J Med Chem. 1989 May;32(5):1057-62.Synthesis and biological evaluation of [125I]- and [123I]-4-iododexetimide, a potent muscarinic cholinergic receptor antagonist. To Reference |
| Ref 12 | Bioorg Med Chem Lett. 2009 Aug 15;19(16):4560-2. Epub 2009 Jul 8.Discovery of (3-endo)-3-(2-cyano-2,2-diphenylethyl)-8,8-dimethyl-8-azoniabicyclo[3.2.1]octane bromide as an efficacious inhaled muscarinic acetylcholine receptor antagonist for the treatment of COPD. To Reference |
| Ref 13 | J Med Chem. 1992 Aug 21;35(17):3270-9.Urea and 2-imidazolidone derivatives of the muscarinic agents oxotremorine and N-methyl-N-(1-methyl-4-pyrrolidino-2-butynyl)acetamide. To Reference |
| Ref 14 | J Med Chem. 1998 Oct 22;41(22):4181-5.Synthesis and modeling studies of a potent conformationally rigid muscarinic agonist: 1-azabicyclo[2.2.1]heptanespirofuranone. To Reference |
| Ref 15 | Bioorg. Med. Chem. Lett. 7(8):979-984 (1997) To Reference |
| Ref 16 | Bioorg. Med. Chem. Lett. 2(8):803-808 (1992) To Reference |
| Ref 17 | J Med Chem. 2007 Apr 19;50(8):1925-32. Epub 2007 Mar 17.Designing active template molecules by combining computational de novo design and human chemist's expertise. To Reference |
| Ref 18 | J Med Chem. 1992 Apr 3;35(7):1280-90.Synthesis and muscarinic activities of quinuclidin-3-yltriazole and -tetrazole derivatives. To Reference |
| Ref 19 | J Med Chem. 2010 Sep 9;53(17):6386-97.Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 receptor agonist with unprecedented selectivity and procognitive potential. To Reference |
| Ref 20 | J Med Chem. 2008 Nov 27;51(22):7094-8.cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain responses against carrageenan-induced hyperalgesia. To Reference |
| Ref 21 | J Med Chem. 1993 Apr 2;36(7):842-7.Design, synthesis, and neurochemical evaluation of 5-(3-alkyl-1,2,4- oxadiazol-5-yl)-1,4,5,6-tetrahydropyrimidines as M1 muscarinic receptor agonists. To Reference |
| Ref 22 | J Med Chem. 1998 Jun 4;41(12):2047-55.6beta-Acetoxynortropane: a potent muscarinic agonist with apparent selectivity toward M2-receptors. To Reference |
| Ref 23 | Bioorg. Med. Chem. Lett. 2(8):791-796 (1992) To Reference |
| Ref 24 | J Med Chem. 2000 Jun 29;43(13):2514-22.6beta-Acyloxy(nor)tropanes: affinities for antagonist/agonist binding sites on transfected and native muscarinic receptors. To Reference |
| Ref 25 | J Med Chem. 1991 Oct;34(10):2984-9.Muscarinic receptor binding profile of para-substituted caramiphen analogues. To Reference |
| Ref 26 | J Med Chem. 1989 Dec;32(12):2573-82.Synthesis and pharmacological evaluation of a series of 4-piperazinylpyrazolo[3,4-b]- and -[4,3-b][1,5]benzodiazepines as potential anxiolytics. To Reference |
| Ref 27 | Bioorg Med Chem Lett. 2008 Jan 15;18(2):825-7. Epub 2007 Nov 17.Design and synthesis of a fluorescent muscarinic antagonist. To Reference |
| Ref 28 | J Nat Prod. 2005 Jul;68(7):1061-5.Nocardimicins A, B, C, D, E, and F, siderophores with muscarinic M3 receptor inhibiting activity from Nocardia sp. TP-A0674. To Reference |
| Ref 29 | Bioorg Med Chem Lett. 2004 Aug 2;14(15):3967-70.Himbacine analogs as muscarinic receptor antagonists--effects of tether and heterocyclic variations. To Reference |
| Ref 30 | J Med Chem. 1990 Feb;33(2):809-14.Chloro-substituted, sterically hindered 5,11-dicarbo analogues of clozapine as potential chiral antipsychotic agents. To Reference |
| Ref 31 | J Med Chem. 1981 Sep;24(9):1021-6.Synthesis of clozapine analogues and their affinity for clozapine and spiroperidol binding sites in rat brain. To Reference |
| Ref 32 | J Med Chem. 2008 Jul 24;51(14):4150-69. Epub 2008 Jun 28.Identification of a potent, selective, and orally active leukotriene a4 hydrolase inhibitor with anti-inflammatory activity. To Reference |
| Ref 33 | J Med Chem. 2002 Dec 5;45(25):5415-8.Improving the oral efficacy of CNS drug candidates: discovery of highly orally efficacious piperidinyl piperidine M2 muscarinic receptor antagonists. To Reference |
| Ref 34 | J Med Chem. 1988 Jul;31(7):1312-6.Heterocyclic muscarinic agonists. Synthesis and biological activity of some bicyclic sulfonium arecoline bioisosteres. To Reference |
| Ref 35 | J Med Chem. 2009 Aug 27;52(16):5076-92.Discovery of novel quaternary ammonium derivatives of (3R)-quinuclidinol esters as potent and long-acting muscarinic antagonists with potential for minimal systemic exposure after inhaled administration: identification of (3R)-3-{[hydroxy(di-2-thienyl)acetyl]oxy}-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane bromide (aclidinium bromide). To Reference |
| Ref 36 | Bioorg. Med. Chem. Lett. 2(8):809-814 (1992) To Reference |
| Ref 37 | Signal transduction underlying carbachol-induced contraction of human urinary bladder. J Pharmacol Exp Ther. 2004 Jun;309(3):1148-53. Epub 2004 Feb 9. To Reference |